Literature DB >> 24767949

Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy.

Valerie Bomben1, Jerrah Holth2, John Reed3, Paige Cramer4, Gary Landreth4, Jeffrey Noebels5.   

Abstract

The nuclear retinoid X receptor agonist, bexarotene, has been implicated in recovery of cognitive function in mouse models of Alzheimer's disease (AD). Since AD genetic mouse models also show abnormal neural hyperexcitability, which may play a destructive role in memory storage and retrieval, we studied whether bexarotene exerted dynamic network effects on electroencephalography cortical spike discharge rate and spectral frequency in an AD (hAPP J20 model) and non-AD (Kv1.1 null) mouse models of epilepsy. We find that oral treatment with bexarotene over 1 week acutely reduced spike discharges in both models and seizures in the Kv1.1 null mouse model without major alterations in the background frequency of brain rhythms. The effect was reversible and exhibited a similar rapid onset in hippocampal slices. While the exact mechanisms are unknown, bexarotene counteracts both amyloid-β-induced and amyloid-β-independent increases in cortical network hyperexcitability.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Bexarotene; Epilepsy; Hyperexcitability

Mesh:

Substances:

Year:  2014        PMID: 24767949      PMCID: PMC4053509          DOI: 10.1016/j.neurobiolaging.2014.03.029

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  22 in total

1.  Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model.

Authors:  Laure Verret; Edward O Mann; Giao B Hang; Albert M I Barth; Inma Cobos; Kaitlyn Ho; Nino Devidze; Eliezer Masliah; Anatol C Kreitzer; Istvan Mody; Lennart Mucke; Jorge J Palop
Journal:  Cell       Date:  2012-04-27       Impact factor: 41.582

Review 2.  Neurotoxicity of amyloid β-protein: synaptic and network dysfunction.

Authors:  Lennart Mucke; Dennis J Selkoe
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

3.  Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Authors:  Nicholas F Fitz; Andrea A Cronican; Iliya Lefterov; Radosveta Koldamova
Journal:  Science       Date:  2013-05-24       Impact factor: 47.728

4.  Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Authors:  Ina Tesseur; Adrian C Lo; Anouk Roberfroid; Sofie Dietvorst; Bianca Van Broeck; Marianne Borgers; Harrie Gijsen; Diederik Moechars; Marc Mercken; John Kemp; Rudi D'Hooge; Bart De Strooper
Journal:  Science       Date:  2013-05-24       Impact factor: 47.728

5.  Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Authors:  Karthikeyan Veeraraghavalu; Can Zhang; Sean Miller; Jasmin K Hefendehl; Tharinda W Rajapaksha; Jason Ulrich; Mathias Jucker; David M Holtzman; Rudolph E Tanzi; Robert Vassar; Sangram S Sisodia
Journal:  Science       Date:  2013-05-24       Impact factor: 47.728

6.  Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Authors:  Ashleigh R Price; Guilian Xu; Zoe B Siemienski; Lisa A Smithson; David R Borchelt; Todd E Golde; Kevin M Felsenstein
Journal:  Science       Date:  2013-05-24       Impact factor: 47.728

7.  Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy.

Authors:  Jerrah K Holth; Valerie C Bomben; J Graham Reed; Taeko Inoue; Linda Younkin; Steven G Younkin; Robia G Pautler; Juan Botas; Jeffrey L Noebels
Journal:  J Neurosci       Date:  2013-01-23       Impact factor: 6.167

8.  Loss of the Kv1.1 potassium channel promotes pathologic sharp waves and high frequency oscillations in in vitro hippocampal slices.

Authors:  Timothy A Simeone; Kristina A Simeone; Kaeli K Samson; Do Young Kim; Jong M Rho
Journal:  Neurobiol Dis       Date:  2013-03-04       Impact factor: 5.996

9.  In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis.

Authors:  Jason D Ulrich; Jack M Burchett; Jessica L Restivo; Dorothy R Schuler; Philip B Verghese; Thomas E Mahan; Gary E Landreth; Joseph M Castellano; Hong Jiang; John R Cirrito; David M Holtzman
Journal:  Mol Neurodegener       Date:  2013-04-19       Impact factor: 14.195

10.  Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice.

Authors:  Katherine D LaClair; Kebreten F Manaye; Dexter L Lee; Joanne S Allard; Alena V Savonenko; Juan C Troncoso; Philip C Wong
Journal:  Mol Neurodegener       Date:  2013-06-13       Impact factor: 14.195

View more
  23 in total

1.  Relaunching an old drug: the potential role of bexarotene in neurodegenerative diseases.

Authors:  Javier Riancho; Maria T Berciano; Jose Berciano; Miguel Lafarga
Journal:  J Neurol       Date:  2016-01-02       Impact factor: 4.849

Review 2.  Epileptic activity in Alzheimer's disease: causes and clinical relevance.

Authors:  Keith A Vossel; Maria C Tartaglia; Haakon B Nygaard; Adam Z Zeman; Bruce L Miller
Journal:  Lancet Neurol       Date:  2017-04       Impact factor: 44.182

Review 3.  Insulin resistance in Alzheimer's disease.

Authors:  Kelly T Dineley; Jordan B Jahrling; Larry Denner
Journal:  Neurobiol Dis       Date:  2014-09-16       Impact factor: 5.996

4.  High-Content Microfluidic Screening Platform Used To Identify σ2R/Tmem97 Binding Ligands that Reduce Age-Dependent Neurodegeneration in C. elegans SC_APP Model.

Authors:  Sudip Mondal; Evan Hegarty; James J Sahn; Luisa L Scott; Sertan Kutal Gökçe; Chris Martin; Navid Ghorashian; Praveen Navoda Satarasinghe; Sangeetha Iyer; Wisath Sae-Lee; Timothy R Hodges; Jonathan T Pierce; Stephen F Martin; Adela Ben-Yakar
Journal:  ACS Chem Neurosci       Date:  2018-02-23       Impact factor: 4.418

5.  Autophagy Induction by Bexarotene Promotes Mitophagy in Presenilin 1 Familial Alzheimer's Disease iPSC-Derived Neural Stem Cells.

Authors:  Patricia Martín-Maestro; Andrew Sproul; Hector Martinez; Dominik Paquet; Meri Gerges; Scott Noggle; Anatoly A Starkov
Journal:  Mol Neurobiol       Date:  2019-06-16       Impact factor: 5.590

6.  Bexarotene Attenuates Focal Cerebral Ischemia-Reperfusion Injury via the Suppression of JNK/Caspase-3 Signaling Pathway.

Authors:  Hailin Liu; Shengwei Liu; Xiaocui Tian; Qian Wang; Jiangyan Rao; Yucun Wang; Fei Xiang; Hang Zheng; Lu Xu; Zhi Dong
Journal:  Neurochem Res       Date:  2019-11-03       Impact factor: 3.996

7.  Calcineurin/NFAT Signaling in Activated Astrocytes Drives Network Hyperexcitability in Aβ-Bearing Mice.

Authors:  Pradoldej Sompol; Jennifer L Furman; Melanie M Pleiss; Susan D Kraner; Irina A Artiushin; Seth R Batten; Jorge E Quintero; Linda A Simmerman; Tina L Beckett; Mark A Lovell; M Paul Murphy; Greg A Gerhardt; Christopher M Norris
Journal:  J Neurosci       Date:  2017-05-30       Impact factor: 6.167

Review 8.  Leveraging preclinical models for the development of Alzheimer disease therapeutics.

Authors:  Kimberly Scearce-Levie; Pascal E Sanchez; Joseph W Lewcock
Journal:  Nat Rev Drug Discov       Date:  2020-04-08       Impact factor: 84.694

Review 9.  Alzheimer's Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function.

Authors:  Amanda M Di Battista; Nicolette M Heinsinger; G William Rebeck
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

10.  Bexarotene-Activated Retinoid X Receptors Regulate Neuronal Differentiation and Dendritic Complexity.

Authors:  Anais Mounier; Danko Georgiev; Kyong Nyon Nam; Nicholas F Fitz; Emilie L Castranio; Cody M Wolfe; Andrea A Cronican; Jonathan Schug; Iliya Lefterov; Radosveta Koldamova
Journal:  J Neurosci       Date:  2015-08-26       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.